UnitedHealthcare · Dupixent EOE · US health-plan appeal rights

Dupixent EOE denied as not medically necessary by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare Dupixent EOE denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Most insurers reverse a medical-necessity denial when the appeal cites the specific clinical guideline (NCCN, ADA, AACE, etc.) that supports the requested treatment for your indication.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-11

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

UnitedHealthcare's specific coverage criteria for dupixent eoe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: OptumRx Dupixent (Dupilumab) for EoE PA

The UnitedHealthcare angle on Dupixent EOE

## Why UnitedHealthcare Denies Dupixent for EoE on Medical-Necessity Grounds

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated condition that can cause progressive esophageal fibrosis and significant impairment of daily function. Dupixent (dupilumab) is the first FDA-approved biologic indicated specifically for EoE in eligible patients. Despite that approval, UnitedHealthcare frequently issues medical-necessity denials, typically because the submitted documentation does not clearly demonstrate that the patient meets each criterion in UHC's published coverage policy or that other required interventions have been tried first.

## Why This Denial Is Appealable

FDA approval establishes a strong foundation for medical-necessity arguments. When a treatment has a labeled indication that matches the patient's confirmed diagnosis and the prescriber has documented that the patient's clinical picture aligns with the criteria in UHC's own policy, a medical-necessity denial is almost always contestable. The denial letter must explain exactly which criterion was deemed unmet — and that explanation is the roadmap for your appeal.

## Federal Appeal Framework

Internal appeal (Level 1): Submit within the deadline stated on your denial letter (typically 180 days for non-grandfathered ACA plans or 60–180 days under ERISA plans). UHC must decide urgent appeals quickly and standard appeals within plan-specified timeframes.
External review (ACA §2719 / ERISA §503): After exhausting one level of internal appeal, you are entitled to an independent external review by an accredited Independent Review Organization (IRO). The IRO's decision is binding on the plan. Request external review within approximately four months (roughly 120–130 days) of your final internal denial — confirm the exact deadline on your denial notice.
Expedited track: If the standard timeline would seriously jeopardize your health, request simultaneous expedited internal and external review.

## Documentation to Gather

1. Confirmed diagnosis: Pathology report showing esophageal eosinophil counts from recent endoscopic biopsies, plus gastroenterologist's diagnosis letter citing the applicable diagnostic criteria. 2. Prior treatment history: Dated records documenting all prior EoE therapies attempted (dietary elimination, proton-pump inhibitor trials, topical corticosteroids, dilation if applicable), with response or failure noted for each. 3. Clinical severity: Chart notes quantifying swallowing symptoms (frequency, severity, impact on nutrition/weight), endoscopic findings, and any eosinophilic inflammation data. 4. Prescriber medical-necessity letter: A letter that maps the patient's documented history and current status directly to each criterion in UHC's EoE coverage policy and the FDA-approved prescribing label.

## Criteria-Mapping Structure

Pull UHC's current medical/coverage policy for dupilumab-EoE (available at uhcprovider.com or upon request). List every requirement verbatim. Alongside each, cite the exact chart entry, date, and provider statement that satisfies it. For any numeric threshold UHC lists (age, eosinophil count, duration), match it to the specific lab or pathology value in the patient's record — do not paraphrase. This parallel structure makes it easy for the reviewer to check off each criterion and leaves no room for a secondary denial on a different criterion.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other denial reasons for UnitedHealthcare Dupixent EOE

denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-11. Editorial standards: denialhelp.com/authors.